Sarat Chandarlapaty

@saratchandarlapaty.bsky.social did:plc:a4s3xgzeyiypg2g63k6b7vuz

Physician Scientist, Medical Oncologist, My lab studies therapy resistance in breast cancer.

No Bluesky desde 20 novembro 2024

Seguidores: 465
Seguindo: 312
Posts: 5
Dias nos rankings: 0

Resumo

Sarat Chandarlapaty (@saratchandarlapaty.bsky.social) é um usuário do Bluesky desde 20 novembro 2024. Tem 465 seguidores, segue 312 contas e publicou 5 posts.

Aparições nos rankings

Os melhores dias em que posts desta conta entraram na lista diária do Debya.

Esta conta ainda não apareceu em um ranking diário.

Posts curtidos recentemente

Curtidas públicas da rede Bluesky.

Avantika Gupta@avantikagupta.bsky.social11/11/2025 02:14
More mechanisms of resistance to anti-HER2 ADCs, this time with a focus on loss of target interaction!
Ver post
Prasad Jallepalli, MD, PhD@prasad.bsky.social05/06/2025 00:27
our lightsaber
Ver post
Memorial Sloan Kettering Cancer Center@mskcancercenter.bsky.social17/05/2025 00:42
🚨 NEW in @natgenet.nature.com: MSK's Dr. Sarat Chandarlapaty and colleagues investigates how APOBEC3 #mutagenesis drives therapy resistance in #BreastCancer. Learn more: www.nature.com/articles/s41...
Ver post
Avantika Gupta@avantikagupta.bsky.social16/05/2025 13:22
So excited to share our latest work with @saratchandarlapaty.bsky.social, Antonio Marra, Andrea Gazzo @mskcancercenter.bsky.social out today in @natgenet.nature.com! We uncover the function and mechanism of APOBEC3-driven therapy resistance in breast cancer. 🧵 1/ www.nature.com/articles/s41...
Ver post
Memorial Sloan Kettering Cancer Center@mskcancercenter.bsky.social01/05/2025 10:14
Join breast medical oncologist Dr. Sarat Chandarlapaty for a major symposium titled “Mutational processes and therapy resistance in breast cancer” today at #AACR25. Learn more: bit.ly/42PdiVE
Ver post

Entre para ver mais

Contas que bloqueia

No Bluesky, bloqueios são registros públicos.

Esta conta não bloqueia ninguém.